TY - JOUR
T1 - Are we closer to having drugs to treat muscle wasting disease?
AU - Morley, John E.
AU - von Haehling, Stephan
AU - Anker, Stefan D.
PY - 2014
Y1 - 2014
N2 - The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
AB - The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=84902548421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902548421&partnerID=8YFLogxK
U2 - 10.1007/s13539-014-0149-7
DO - 10.1007/s13539-014-0149-7
M3 - Article
AN - SCOPUS:84902548421
VL - 5
SP - 83
EP - 87
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
SN - 2190-5991
IS - 2
ER -